SCHEMBL4565974

SCHEMBL4565974

O=C(Nc1cc(NC(=O)c2ccccc2)c(C(=O)O)nc1C(=O)O)c1ccccc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 5/20 0.64
KMT2A Q03164 5/20 0.64
PKM P14618 3/20 0.64
MAPT P10636 2/20 0.64
GRIK1 P39086 1/20 0.64
TDP1 Q9NUW8 1/20 0.64
TP53 P04637 2/20 0.56
MDM4 O15151 1/20 0.56
NPC1 O15118 3/20 0.53
RAB9A P51151 3/20 0.53
CYP1A2 P05177 1/20 0.53
CYP3A4 P08684 1/20 0.53
CYP2D6 P10635 1/20 0.53
CYP2C9 P11712 1/20 0.53
CYP2C19 P33261 1/20 0.53
HDAC1 Q13547 2/20 0.51
HDAC2 Q92769 2/20 0.51
HDAC3 O15379 1/20 0.51
MAPK1 P28482 1/20 0.51
POLB P06746 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4565707 0.80 MEN1 (0.55) MEN1KMT2APKMMAPTGRIK1
SCHEMBL2801723 0.78 KMT2A (0.54) MEN1KMT2APKMMAPTGRIK1
SCHEMBL1056451 0.78 KMT2A (1.00) MEN1KMT2APKMMAPTGRIK1
SCHEMBL1110180 0.76 MDM4 (0.73) MEN1KMT2APKMMAPTGRIK1
SCHEMBL27874235 0.76 KDR (0.63) MEN1KMT2APKMMAPTGRIK1
SCHEMBL12510751 0.76 HDAC1 (0.67) MEN1KMT2APKMMAPTGRIK1
SCHEMBL4934571 0.75 MEN1 (0.50) MEN1KMT2APKMMAPTGRIK1
SCHEMBL5178629 0.73 HDAC1 (0.69) MEN1KMT2APKMMAPTGRIK1
SCHEMBL3299661 0.72 ADORA1 (0.70) MEN1KMT2ANPC1RAB9ACYP1A2
SCHEMBL11831465 0.72 MEN1 (0.64) MEN1KMT2AMAPTTP53NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040048889-A1 Use of non-competitive and selective glur5 antagonists as gultamate receptor modulating compounds NEUROSEARCH A/S (DK) 2004-03-11 US claimed
EP-1355640-A1 USE OF NON-COMPETITIVE AND SELECTIVE GLUR5 ANTAGONISTS AS GLUTAMATE RECEPTOR MODULATING COMPOUNDS NEUROSEARCH A/S (DK) 2003-10-29 EP claimed
WO-2002058691-A1 USE OF NON-COMPETITIVE AND SELECTIVE GLUR5 ANTAGONISTS AS GLUTAMATE RECEPTOR MODULATING COMPOUNDS NEUROSEARCH A/S (DK) 2002-08-01 WO claimed
US-7488756-B2 Use of non-competitive and selective GluR5 antagonists as glutamate receptor modulating compounds NEUROSEARCH A/S (DK) 2009-02-10 US disclosed
US-20040048889-A1 Use of non-competitive and selective glur5 antagonists as gultamate receptor modulating compounds NEUROSEARCH A/S (DK) 2004-03-11 US disclosed
EP-1355640-A1 USE OF NON-COMPETITIVE AND SELECTIVE GLUR5 ANTAGONISTS AS GLUTAMATE RECEPTOR MODULATING COMPOUNDS NEUROSEARCH A/S (DK) 2003-10-29 EP disclosed
WO-2002058691-A1 USE OF NON-COMPETITIVE AND SELECTIVE GLUR5 ANTAGONISTS AS GLUTAMATE RECEPTOR MODULATING COMPOUNDS NEUROSEARCH A/S (DK) 2002-08-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040048889-A1 Use of non-competitive and selective glur5 antagonists as gultamate receptor modulating compounds GRM5, GRIK5, GRIN1 MEN1 4791/4885KMT2A 1332/4885PKM 3013/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.